Oncology & Cancer

Interim scan during prostate cancer therapy helps guide treatment

New prostate cancer research shows that adding an interim scan during therapy can help guide a patient's treatment. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging of patients with metastatic ...

Oncology & Cancer

Drug combo slows progression in advanced breast cancer

(HealthDay)—Treatment with a combination of alpelisib and fulvestrant prolongs progression-free survival among patients with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative ...

Oncology & Cancer

Choosing the right drug to fight cancer

Canadian researchers have discovered a molecular indicator of a mechanism that drives cancer progression, giving doctors the possibility of using precision medicine, that is, choosing which patients will respond to a particular ...

Oncology & Cancer

POLO trial for advanced pancreatic cancer: a new standard of care

Treatment with the drug olaparib significantly reduced the risk of disease progression or death from metastatic pancreatic cancer, according to findings from the recently completed, international, phase-III POLO (Pancreas ...

Oncology & Cancer

Trial of metformin for non-small cell lung cancer

Initial results of NRG-LU001 indicate that, although the diabetes agent metformin was well-tolerated by patients, the agent has not clearly improved progression-free survival (PFS) or overall survival (OS) for trial participants ...

Oncology & Cancer

Entrectinib gets edge over crizotinib against ROS1+ lung cancer

Crizotinib and entrectinib are both active against ROS1+ non-small cell lung cancer. But which is best? The answer seems easy: Just compare the drugs' clinical trial results. However, not all trials are created equal, and ...

page 1 from 23